Table 4.
Correlation of NSDHL and NCEH1 expression with clinicopathological features in gastric cancer
| Clinicopathological features | NSDHL and NCEH1 (‐) | NSDHL and NCEH1 (+) | Case | p‐values* |
|---|---|---|---|---|
| Age (year) | ||||
| ≥60 | 10 (14.9%) | 57 (85.1%) | 67 | .804 |
| ≤59 | 5 (13.2%) | 33 (86.8%) | 38 | |
| Sex | ||||
| Male | 11 (14.9%) | 63 (85.1%) | 74 | .793 |
| Female | 4 (12.9%) | 27 (87.1%) | 31 | |
| Histology classification | ||||
| Adenocarcinoma | 10 (11.5%) | 77 (88.5%) | 87 | .072 |
| Signet‐ring cell carcinoma | 5 (27.8%) | 13 (72.2%) | 18 | |
| Histological grade | ||||
| I | 7 (9.7%) | 65 (90.3%) | 72 | .048 |
| II and III | 8 (24.2%) | 25 (75.8%) | 33 | |
| Lymph node metastasis | ||||
| Positive | 7 (11.5%) | 54 (88.5%) | 61 | .333 |
| Negative | 8 (18.2%) | 36 (81.8%) | 44 | |
| TNM Staging | ||||
| I | 10 (25.6%) | 29 (74.4%) | 39 | .011 |
| Ⅱ‐Ⅳ | 5 (7.6%) | 61 (92.4%) | 66 | |
*
The p‐values were determined by the chi‐square test.